José Jimenez

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

Maurizio Scaltriti, Chandra Verma, Marta Guzmán et al. · Oncogene · 2008 · 444 citations

Medicine, Cancer Biology, Oncology +15

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez et al. · Annals of Oncology · 2018 · 427 citations · Full text

Medicine, Molecular Biology, Oncology +17

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

Pieter J.A. Eichhorn, Laura Rodón, Alba Gonzàlez-Juncà et al. · Nature Medicine · 2012 · 404 citations

Life Sciences, Molecular Biology, Oncology +12

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients

Maurizio Scaltriti, Pieter J.A. Eichhorn, Javier Cortés et al. · Proceedings of the National Academy of Sciences · 2011 · 332 citations

Medicine, Genetics, Oncology +17

<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

Ian J. Majewski, Paolo Nucíforo, Lorenza Mittempergher et al. · Journal of Clinical Oncology · 2015 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17